Form 4: Septerna Director Bernard Coulie Granted Significant Stock Options

Septerna, Inc. Director Bernard Coulie was granted 16,623 stock options with an exercise price of $10.24, vesting by June 2026 or the next annual meeting, as reported in a recent SEC Form 4 filing.

Summary

• Bernard Coulie, a Director of Septerna, Inc. (SEPN), was granted 16,623 stock options on June 17, 2025.
• The exercise price for these stock options is $10.24 per share.
• The options will vest in full upon the earlier of June 17, 2026, or the Issuer's next annual meeting of stockholders.
• Vesting is contingent on Mr. Coulie's continued service to Septerna, Inc. through the vesting date.
• The stock options have an expiration date of June 16, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine event that aligns the director's interests with shareholder value, generally viewed as a positive for corporate governance and long-term performance incentives, without indicating any negative operational or financial news.

Positives

• The grant of stock options to Director Bernard Coulie aligns his financial interests with those of the shareholders, incentivizing long-term company performance and value creation.

Negatives

• NA

Risks

• The ultimate value of the stock options is dependent on the future market price of Septerna, Inc. common stock exceeding the exercise price of $10.24, meaning the options could be worthless if the stock price does not appreciate above this level.

Future Outlook

The vesting schedule for the granted stock options implies a future commitment from Director Bernard Coulie to continued service to Septerna, Inc. until at least June 17, 2026, or the company's next annual meeting, which provides stability in board leadership.

Industry Context

The grant of stock options to a director is a common and standard practice across various industries, including the biotechnology and pharmaceutical sectors, to attract, retain, and incentivize key leadership by aligning their compensation with the long-term performance and growth of the company.

Comparison to Industry Standards

• The grant of stock options as a form of director compensation is a widely adopted practice consistent with corporate governance standards in publicly traded companies, including those in the biotechnology sector like Septerna, Inc.
• Similar equity compensation structures are observed in comparable companies such as Moderna (MRNA) or BioNTech (BNTX), where stock options and restricted stock units are routinely used to incentivize executives and board members, though the specific size and terms of grants vary based on company stage, market capitalization, and individual roles.

Related Party Transactions

• The grant of 16,623 stock options to Director Bernard Coulie represents a compensation transaction between the company and a related party (an insider).

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders if the stock price appreciates above the exercise price.

Next Steps

• The stock options will vest in full upon the earlier of June 17, 2026, or Septerna's next annual meeting of stockholders, subject to Bernard Coulie's continued service to the Issuer.

Key Dates

Keywords

Septerna, SEPN, stock options, insider transaction, Form 4, beneficial ownership, director compensation, equity grant